Core Insights - Niagen Bioscience Inc. reported strong financial performance for 2025, with net revenue of $129.4 million, reflecting a 30% year-over-year growth, and a net income of $17.4 million [5][25][30] - The company is well-positioned for 2026, despite increased competition in the NAD market, and continues to lead in NAD science with significant research backing [6][13] - The company has secured a patent for NIAGEN Plus, which will expand its product offerings into intravenous and injectable formulations, and plans to launch at-home injection kits in 2026 [8][9] Financial Performance - In Q4 2025, revenue reached $33.8 million, a 16% increase from the previous year, driven primarily by e-commerce sales [5][27] - Gross margin improved to 64.3% for the full year, indicating enhanced operational efficiency [25] - Selling and marketing expenses were 30.8% of sales in Q4, reflecting targeted investments in brand awareness [29] Research and Development - Niagen Bioscience Inc. remains the global leader in NAD science, with 29 studies published since the last earnings call, including clinical studies demonstrating the benefits of nicotinamide riboside (NR) [6][15] - Notable studies include findings that NR supplementation can slow aging and improve fatigue, sleep quality, and cognitive function [7][16][20] - The company is focusing on the therapeutic potential of NR in neurodegenerative diseases, including ongoing collaborations to explore its preventive effects in Parkinson's disease [18][57] Product Development and Market Expansion - The company plans to expand its presence in the beauty and cosmetics market, following the successful launch of Tru Niagen in beauty [9][46] - Niagen Plus will be introduced in over 1,200 health clinics, with plans to partner with telehealth providers for distribution [8][9] - The company is also exploring new retail channels and international markets, particularly in Asia and the EU [46] Legal and Regulatory Environment - Niagen Bioscience Inc. is currently involved in litigation against the FDA regarding the marketing of NMN as a dietary supplement, believing it has a strong case [10][55] - The company has acquired patents for multiple NR salt forms, enhancing its intellectual property portfolio and market position [11]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.8 million, a 16% year-over-year increase, with net income of $4.1 million [10] - For the full year 2025, net revenue reached $129.4 million, representing a 30% growth year-over-year, and net income was $17.4 million [10][38] - The company ended the year with $64.8 million in cash and no debt, indicating strong financial stability [10][43] Business Line Data and Key Metrics Changes - Revenue from the Tru Niagen product line grew by 21% to $27.5 million, driven primarily by e-commerce sales of $20.2 million, which increased by 17% [40] - Niagen ingredient revenue was $5.6 million, up 5% year-over-year, with food-grade sales at $4.7 million and pharma-grade sales at $900,000 [40] - Revenue from B2B distribution partners totaled $7.3 million, supported by strategic partnerships [41] Market Data and Key Metrics Changes - The company is expanding its presence in over 1,200 health clinics and plans to launch at-home Niagen Plus injection kits through a telehealth platform [15] - The company anticipates continued growth in the Asia-Pacific markets and selective retail channels [66] Company Strategy and Development Direction - The company aims to focus on NAD science and intellectual property while exiting non-core activities, as evidenced by the sale of the ChromaDex Reference Standards business [21][45] - Plans include expanding into the beauty cosmetics market and launching new products, including topical products featuring Niagen [16][66] - The company is committed to maintaining its leadership in NAD science and enhancing its product offerings through strategic R&D investments [20][48] Management's Comments on Operating Environment and Future Outlook - Management acknowledged increased competition in the NAD space but emphasized the company's strong foundation and expertise [11] - The company expects to achieve 10%-15% growth in net sales for 2026, with a slight improvement in gross margin [45][46] - Management expressed confidence in the company's ability to deliver value to stakeholders and maintain its market position [48] Other Important Information - The company secured a patent for intravenous and injectable formulations of NR, indicating potential for new product development [15] - Ongoing litigation against the FDA regarding NMN products is expected to have minimal impact on legal expenses [76] Q&A Session Summary Question: Discussion on injections and telehealth platform - Management confirmed that initially, there will be one SKU for injections, targeting the biohacker community and those interested in longevity interventions [53] Question: Guidance for 2026 - Management indicated that the guidance is conservative, reflecting a cautious approach to revenue projections [58] Question: Growth drivers for 2026 - Management expects growth from existing products, new distribution channels, and increased brand awareness [66] Question: Lawsuit against the FDA - Management believes the case will likely result in a summary judgment and is optimistic about a favorable outcome [76] Question: Share repurchase strategy - Management plans to utilize the remaining $9.75 million of the buyback program, viewing it as a good investment at current prices [79]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.8 million, a 16% year-over-year increase, with net income of $4.1 million [6][24] - For the full year 2025, net revenue reached $129.4 million, representing a 30% growth year-over-year, and net income was $17.4 million [7][26] - The company ended the year with $64.8 million in cash and no debt, reinforcing financial stability [30] Business Line Data and Key Metrics Changes - Revenue from Tru Niagen grew by 21% to $27.5 million, primarily driven by e-commerce sales of $20.2 million, which increased by 17% [26][28] - Niagen ingredient revenue was $5.6 million, up 5% year-over-year, with food-grade sales at $4.7 million and pharma-grade sales at $900,000 [27] - Revenue from B2B distribution partners totaled $7.3 million, supported by strategic partnerships [27] Market Data and Key Metrics Changes - The company is expanding its presence in over 1,200 health clinics and plans to launch at-home injection kits through a telehealth platform [10] - The market for NAD products is growing, with increased competition, particularly from NMN products [8][11] Company Strategy and Development Direction - The company aims to build on its strong foundation in NAD science, focusing on expanding its product offerings and market presence [8][10] - Plans include launching Niagen Plus branded at-home injection kits and expanding into the beauty cosmetics market [10][11] - The company is pursuing litigation against the FDA regarding NMN products, believing it has a strong case [11][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering strong performance in 2026 despite challenges from increased competition [8] - The company anticipates 10%-15% growth in net sales for 2026, with a slight improvement in gross margin [32][33] - Management emphasized the importance of scientific integrity and continued investment in R&D to support innovation [29] Other Important Information - The company divested its ChromaDex Reference Standards business to streamline operations and focus on core activities [13][32] - A recent patent was secured for NR and derivatives in intravenous and injectable formulations, indicating potential growth opportunities [10] Q&A Session Summary Question: Discussion on injections and SKUs - The company plans to initially offer one SKU for injections, targeting the biohacker community and expanding to other audiences later [40] Question: Guidance for the year - Management indicated that guidance is conservative, reflecting a cautious approach to revenue projections [43] Question: Growth drivers for the year - Growth is expected from existing products, new distribution channels, and increased awareness of Niagen and Tru Niagen [50] Question: Legal proceedings against the FDA - Management believes the lawsuit will not significantly impact costs and expects a summary judgment [62] Question: Share repurchase strategy - The company plans to utilize its $10 million buyback program more actively in the future [65]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.8 million, a 16% year-over-year increase, with net income of $4.1 million [5][21] - For the full year 2025, net revenue reached $129.4 million, representing a 30% growth year-over-year, and net income was $17.4 million compared to $8.6 million in 2024 [5][23] - The company ended the year with $64.8 million in cash and no debt, reinforcing financial stability [5][26] Business Line Data and Key Metrics Changes - Revenue from Tru Niagen grew by 21% to $27.5 million, primarily driven by e-commerce sales of $20.2 million, up 17% [23][24] - Niagen ingredient revenue was $5.6 million, a 5% increase year-over-year, with food-grade sales at $4.7 million and pharma-grade sales at $900,000 [24] - Revenue from B2B distribution partners totaled $7.3 million, supported by strategic partnerships [24] Market Data and Key Metrics Changes - The company is expanding its presence in over 1,200 health clinics and plans to launch at-home injection kits through a telehealth platform in 2026 [8] - The company anticipates continued growth in Asia-Pacific markets and selective retail channels [47] Company Strategy and Development Direction - The company aims to focus on NAD science and has divested non-core activities, such as the sale of the ChromaDex Reference Standards business [11][29] - Plans include launching Niagen Plus branded at-home injection kits and expanding into the beauty cosmetics market [8][9] - The company is pursuing litigation against the FDA regarding NMN products, believing it has a strong case [9][56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering strong performance in 2026 despite increased competition in the NAD space [6][31] - The company expects 10%-15% growth in net sales for 2026, with a slight improvement in gross margin due to supply chain efficiencies [29][30] - Management emphasized the importance of scientific integrity and continued investment in R&D to support innovation [25][30] Other Important Information - The company secured a patent for intravenous and injectable formulations of NR, indicating potential for new product offerings [8] - Management highlighted the therapeutic potential of NR supplementation based on recent studies, including benefits for long COVID and cognitive health [14][16] Q&A Session Summary Question: Discussion on injections and SKUs - The company plans to start with one SKU for injections, targeting the biohacker community and those interested in longevity interventions [35][36] Question: Guidance for the year - Management indicated that guidance is conservative, reflecting a cautious approach to revenue projections [40] Question: Growth drivers for the year - Growth is expected from existing products, new IV and beauty products, and expanded distribution channels [46][47] Question: Lawsuit against the FDA - Management believes the lawsuit will not significantly impact costs and anticipates a summary judgment [56][57] Question: Share repurchase strategy - The company plans to utilize its $10 million buyback program more actively in the future [60]

Niagen Bioscience, Inc. Earnings Presentation Fourth Quarter and Full Year 2025 Nasdaq: NAGE | March 4, 2026 Safe Harbor Statement This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect the current view about future events. Statemen ...

Summary of Niagen Bioscience FY Conference Call Company Overview - Niagen Bioscience, formerly known as ChromaDex, focuses on nicotinamide riboside (NR), a precursor to the coenzyme NAD (nicotinamide adenine dinucleotide) [2][3] - The company has over 100 patents related to NAD precursors and has conducted 41 clinical studies and over 100 preclinical studies on Niagen [4] Core Product and Market Position - Niagen is positioned as the leading product in the NAD supplement space, with claims of improving cellular resilience and healthspan, particularly in aging populations [3][10] - The company has diversified its offerings, selling Niagen as a dietary supplement, a B2B ingredient, and as an injectable product [5][13] Financial Performance - Niagen Bioscience reported approximately $125 million in revenue and $20 million in net income over the last 12 months, with a strong balance sheet showing nearly $65 million in cash and no debt [20] - The company operates conservatively, focusing on maintaining a strong cash position and exploring growth opportunities [28] Growth Opportunities - The NAD IV market is rapidly growing, potentially surpassing the supplement market, with initial retail sales estimated between $50-$100 million in the first year [24][23] - Plans to launch a telehealth business for at-home injections are expected to cater to the growing interest in self-administered health products [15] Research and Development - Niagen Bioscience emphasizes R&D, investing significantly in understanding its products and their effects, with a commitment to quality science [18] - The company is exploring applications in orphan diseases, particularly those that cause rapid aging in children, with promising results from clinical studies [16] Skincare Market Potential - The company is pursuing opportunities in the skincare market, leveraging niacinamide, which elevates NAD but is less effective than NR [17] - Discussions with major global skincare companies are ongoing, with expectations for announcements in 2026 [18] Strategic Partnerships - Niagen has formed partnerships with networks of healthcare practitioners to educate consumers and promote its products [26] - The company aims to differentiate itself through scientific credibility and informed marketing strategies [27] Market Challenges - The company faces challenges from competitors and infringers in the NAD space, which can impact sales and market perception [22] - The stock has shown volatility, attributed to external market factors rather than company performance [20] Conclusion - Niagen Bioscience is well-positioned in the growing NAD market, with a strong financial foundation and diverse product offerings. The company is focused on expanding its market presence through innovative products, strategic partnerships, and a commitment to research and development [20][28]

Core Viewpoint - Niagen Bioscience, Inc. has partnered with Truemed to allow qualified customers to purchase its leading NAD+ supplement, Tru Niagen, using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds, enhancing accessibility for consumers seeking nutritional support for cellular health [1][2][3] Group 1: Partnership and Accessibility - The partnership with Truemed enables a streamlined checkout experience for customers using HSA/FSA funds to purchase Tru Niagen [2][4] - Eligible customers can obtain a Letter of Medical Necessity (LMN) from a licensed provider to support their HSA/FSA eligibility [4][7] Group 2: Product Information - Tru Niagen is recognized as the number one NAD+ supplement in the United States, featuring Niagen, a patented form of nicotinamide riboside (NR), which is a highly efficient NAD+ booster [3][11] - The product is supported by over 40 peer-reviewed human clinical studies and more than 500 published scientific papers, highlighting its rigorous quality and scientific standards [3][11] Group 3: Company Background - Niagen Bioscience is a leader in NAD+ science and healthy-aging research, dedicated to advancing healthspan through innovative NAD+-boosting solutions [8][9] - The company collaborates with renowned scientists and research institutions globally to explore the potential of NAD+, which is crucial for cellular health and declines with age [9][10]

Financial Data and Key Metrics Changes - The company reported a record revenue of $34 million for Q3 2025, representing a 33% increase year over year, and a net income of $4.6 million compared to $1.9 million in the same period last year [5][14][17] - The cash position at the end of the quarter was $64.3 million with no debt [5][17] - Gross margin improved to 64.5%, up 100 basis points from 63.5% a year ago [16] Business Line Data and Key Metrics Changes - E-commerce business generated net sales of $19 million, a 29% increase year over year [5][14] - The distribution business saw a significant growth of 109% year over year, achieving $7 million in revenue [5][14] - Niagen ingredient business remained steady with revenue of $6.9 million, a 4% increase year over year [14] Market Data and Key Metrics Changes - The NAD market is expanding rapidly, with significant opportunities in skincare, cosmetics, food, beverage, and drug applications [8][10] - The company has onboarded over 1,000 wellness and healthcare clinics across the U.S. to offer the Niagen Plus product line [7][8] Company Strategy and Development Direction - The company aims to educate healthcare practitioners and consumers about Niagen as the most effective NAD booster available [6][8] - Plans to expand distribution of at-home injection kits via a telehealth platform are underway [7][34] - The company is considering establishing a standalone entity to pursue pharmaceutical applications of nicotinamide riboside, particularly for Parkinson's disease [42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the updated full-year revenue growth guidance, revised from 22%-27% to 25%-30% year-over-year [18] - The company anticipates that gross margins will normalize on a quarterly basis moving forward, despite improvements year-over-year [16][19] - Management noted that the FDA's recent decision regarding NMN has not significantly impacted consumer purchasing behavior [36][37] Other Important Information - The company has over 40 peer-reviewed clinical studies supporting the efficacy of Niagen [9][12] - The National Advertising Division recently supported the company's position against false claims made by competitors regarding NAD products [10] Q&A Session Summary Question: What is the uptake looking like with the new partnership for IV? - Management indicated it is too early to provide feedback as the partnership just began reselling the material [24] Question: How does the "About NAD" site fit into the marketing funnel? - The site serves as an objective resource for information on NAD and is not part of the purchasing funnel [26] Question: Are at-home injection kits available in all clinics? - Currently, the kits are available in clinics, and the rollout for online purchasing is expected to take several months [33] Question: Has the FDA's announcement on NMN changed consumer purchasing behavior? - Management noted no significant changes in purchasing behavior since the announcement [36] Question: Will the company establish a standalone entity for pharmaceutical applications? - Management confirmed that establishing a standalone entity for pharmaceutical pursuits is likely, depending on study results and discussions with pharma companies [42]

Summary of Niagen Bioscience Conference Call Company Overview - Niagen Bioscience is focused on the development and commercialization of nicotinamide riboside (Niagen), a molecule that elevates NAD levels in cells, which is crucial for energy metabolism and cellular repair [5][7][8] - The company has over 90 patents protecting its core molecule and has built a strong scientific foundation with extensive research [8][14] Core Points and Arguments - **Scientific Research and Clinical Studies**: Niagen has conducted 40 peer-reviewed clinical studies demonstrating the safety and efficacy of its product, particularly in age-related conditions [7][18][24] - **Unique Positioning**: Unlike many dietary supplement companies, Niagen is rooted in scientific research and intellectual property, which differentiates it from competitors that primarily engage in marketing [11][14][17] - **Regulatory Challenges**: The company faces strict regulations that prevent it from making health claims typically associated with drugs, which influences its marketing strategy [23][24] - **Market Strategy**: Niagen relies on word-of-mouth and expert endorsements rather than direct consumer claims to build trust and credibility [24][25] Recent Developments - **Product Launches**: The company launched the Niagen Plus line, which includes IV products and at-home injectables, generating significant media attention and interest from celebrities and influencers [34][35][40] - **Clinical Trials**: A phase three clinical study on Parkinson's disease with 400 participants is nearing completion, which could significantly impact the company's valuation and credibility in the biotech space [18][54] - **Financial Health**: Niagen is cash flow positive, has no debt, and does not require additional capital for its operations, which is atypical for biotech companies [52][54] Potential Risks and Concerns - **Market Competition**: The rise of fraudulent companies claiming to offer NAD products poses a risk to the overall market perception and could impact Niagen's reputation [27][29] - **Consumer Education**: There is a need to educate consumers about the differences between Niagen and other NAD products, particularly regarding bioavailability and efficacy [27][37] Future Outlook - **Injectable Products**: The company plans to introduce a self-injection product within the next year, tapping into the growing trend of self-administered health solutions [49][50] - **Pharmaceutical Opportunities**: Niagen is exploring drug indications beyond dietary supplements, which could enhance its market position and attract sophisticated investors [54] Conclusion - Niagen Bioscience is well-positioned in the NAD market with a strong scientific foundation, innovative products, and a clear strategy to navigate regulatory challenges while maintaining financial stability. The company's focus on research and quality sets it apart from competitors, and its future product developments could significantly expand its market reach and impact.

Financial Data and Key Metrics Changes - In Q1 2025, the company reported revenues of $30,500,000, representing a 38% year-over-year increase [8][18] - Net income for the quarter was $5,100,000, compared to a net loss of $500,000 in Q1 2024 [21] - Cash generated from operations was $7,900,000, a significant increase from $300,000 in the same period last year [22] - The company ended the quarter with $55,600,000 in cash and no debt, maintaining strong liquidity [21] Business Line Data and Key Metrics Changes - E-commerce sales grew by 31% year-over-year, contributing significantly to revenue growth [9][18] - The food grade and pharmaceutical grade Niagen ingredient business saw a 95% increase, reaching $8,000,000 [9][18] - Gross margin improved to 63.4%, up from 60.7% a year ago, driven by a favorable product mix and cost savings [18] Market Data and Key Metrics Changes - The demand for NAD-boosting products is surging, with increasing consumer awareness of Niagen as a trusted solution [12][14] - The company aims to expand its presence in clinics, targeting 1,000 clinics by the end of 2025, with a potential addressable market of 2,000 to 3,000 clinics [42] Company Strategy and Development Direction - The company is focused on reinforcing Niagen as the leading NAD-boosting solution, aligning its brand with its mission of promoting healthy aging [15][16] - The pharmaceutical application of nicotinamide riboside (NR) is a key strategic initiative, with ongoing studies and FDA dialogues [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustained momentum across e-commerce and ingredient businesses, raising the full-year growth outlook to 20% to 25% [22][23] - The company is committed to operational discipline and efficiency, with a focus on long-term profitability [26] Other Important Information - The company announced a new composition of matter patent granted in March, broadening its patent portfolio [11] - Management highlighted the importance of maintaining integrity and scientific rigor in the NAD supplement market [13][14] Q&A Session Summary Question: What are the emerging tailwinds for NIAGEN IV product adoption? - Management noted significant interest from clinics and physicians, with 600 clinics currently offering NIAGEN IV and expectations for increased sales [28][32] Question: Are there new promotional strategies for e-commerce? - Management indicated a focus on profitability and efficiency, with plans to increase presence on platforms like TikTok and engage with influencers [35][37] Question: What is the potential market for NIAGEN plus? - Management aims to onboard 1,000 clinics by year-end, with a larger addressable market identified [42] Question: What is the status of the injectable NIAGEN plus? - Management confirmed that an at-home version is in development, expected to be available by Q4 2025 [72][73] Question: What is the status of the FDA discussions regarding ataxia telangiectasia? - Active discussions are ongoing with the FDA, with a pre-IND submission made and feedback received [90][91]